8-K: Zynex Reports Steady Growth in Q3 2024, Achieves FDA Clearance for New TensWave Device

Zynex, Inc. announced a 13% year-over-year increase in orders and $50 million in net revenue for the third quarter of 2024, along with FDA clearance for their new TensWave device.

Summary

• Zynex reported a 13% increase in orders year-over-year for the third quarter of 2024.
• Net revenue for Q3 2024 was $50.0 million, slightly up from $49.9 million in the same quarter of the previous year.
• The company achieved a net income of $2.4 million, or $0.07 per diluted share, in Q3 2024, compared to $3.6 million, or $0.10 per diluted share, in Q3 2023.
• Cash flow from operations was $7.1 million for the quarter.
• Zynex received FDA clearance for their new TensWave device during the quarter.
• Revenue per sales representative increased by 25% year-over-year to approximately $530,000.
• The company expects at least $53.6 million in revenue and $0.09 diluted EPS for the fourth quarter of 2024.
• Full year 2024 net revenue is expected to be at least $200 million, a 9% increase from 2023, with diluted EPS of at least $0.20 per share.
• Adjusted EBITDA for the third quarter was $5.1 million, compared to $7.3 million in the same period last year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the increase in orders, FDA clearance, and positive cash flow, but tempered by the decrease in net income and adjusted EBITDA compared to the previous year. The company is showing steady growth and is on track to meet its full year guidance.

Positives

• Zynex experienced a 13% year-over-year increase in orders, indicating strong demand for their products.
• The company achieved positive cash flow from operations of $7.1 million in Q3 2024.
• The FDA clearance of the TensWave device expands their product portfolio and addresses a market gap for high-quality TENS devices.
• Revenue per sales representative increased by 25% year-over-year, demonstrating improved sales force productivity.
• Zynex is projecting a return to 20% top-line growth in its pain management division in 2025.
• Cash and cash equivalents increased 22% from June 30, 2024 to $37.6 million at September 30, 2024.

Negatives

• Net income decreased to $2.4 million in Q3 2024 from $3.6 million in Q3 2023.
• Adjusted EBITDA decreased to $5.1 million in Q3 2024 from $7.3 million in Q3 2023.
• Gross profit margin decreased slightly to 80% from 81% in the prior year quarter.
• Sales and marketing expenses decreased due to reduced sales force headcount, which may impact future growth if not managed carefully.
• General and administrative expenses increased to $15.3 million from $12.7 million in the prior year period.

Risks

• The company's future performance is subject to risks including the acceptance of new products by doctors and hospitals.
• Zynex faces competition from larger companies with greater financial resources.
• The company is dependent on reimbursement for its products from health insurance companies.
• Zynex relies on third-party manufacturers to produce their products on time and to their specifications.
• The company's sales strategy depends on a strong direct sales force.
• Economic factors, such as interest rate fluctuations, could impact the company's performance.

Future Outlook

Zynex anticipates a return to 20% top-line growth in its pain management division in 2025 and expects at least $53.6 million in revenue and $0.09 diluted EPS for the fourth quarter of 2024. The company projects full year 2024 net revenue of at least $200 million, a 9% increase from 2023, and diluted EPS of at least $0.20 per share.

Management Comments

• Thomas Sandgaard, President and CEO of Zynex, stated that the company continued its steady growth in orders and is positioned for long-term profitable growth.
• Sandgaard noted that positive cash flow remains strong and both revenue and earnings were within guidance for the third quarter.
• Sandgaard highlighted the company's success in diversifying revenue streams through increased orders in orthopedic products.
• Sandgaard mentioned that the FDA clearance for the new TensWave device builds on their strong legacy of innovation in pain management.
• Sandgaard believes their strategy is positioning them to become the world's premier provider of holistic, non-invasive approaches to pain management.

Industry Context

The announcement reflects a continued focus on non-invasive pain management solutions, aligning with a broader trend in the medical device industry to reduce reliance on opioids. The FDA clearance of the TensWave device positions Zynex to compete more effectively in the TENS therapy market.

Comparison to Industry Standards

• Zynex's revenue growth of approximately 9% for the full year 2024 is moderate compared to some high-growth medical device companies, but it is a positive sign given the current economic environment.
• The company's gross profit margin of 80% is relatively strong, indicating efficient cost management in production and sales.
• Compared to companies like Nevro Corp (NVRO) which focuses on spinal cord stimulation, Zynex's approach with TENS devices offers a different non-invasive pain management option.
• Companies like Medtronic (MDT) have a broader portfolio, but Zynex's focus on specific pain management devices allows for specialization and targeted market penetration.
• The 25% increase in revenue per sales rep is a positive indicator of sales efficiency, which is a key metric for medical device companies.

Stakeholder Impact

• Shareholders may view the results positively due to the increase in orders and revenue, but may be concerned about the decrease in net income and adjusted EBITDA.
• Employees may be impacted by the decrease in sales force headcount, but the increase in revenue per sales rep could indicate improved productivity.
• Customers will benefit from the new TensWave device, which offers a safe and effective alternative to pain management.
• Suppliers may see increased demand for components as Zynex expands its product offerings.
• Creditors may view the positive cash flow and working capital as a sign of financial stability.

Next Steps

• Zynex will continue to diversify its pain management revenue stream with the introduction of new therapy products.
• The company will aggressively promote products from its salesforce to ensure sustained profitable growth.
• Zynex will focus on expediting the onboarding of new sales representatives while maintaining a high standard for productivity.

Key Dates

Keywords

medical devices, pain management, rehabilitation, TENS, FDA clearance, net revenue, net income, EBITDA, orthopedic products, non-invasive